Are you a biotech company developing innovative therapies, diagnostics, or digital tools in Alzheimer's disease or neurodegeneration? CTAD25 invites you to take part in a unique visibility and networking opportunity designed to connect emerging biotechs with key clinical trial leader, researcher, and investors.

CTAD is the only conference that brings together the world's leading AD/ADRD clinical trialists working in academia, industry and not-for-profit organizations and has a focus on Alzheimer's Disease therapeutic tirals. CTAD is dedicated to promoting the professional development of these emerging leaders to ensure their success and career advancement.